Market Closed -
Other stock markets
|
After market 04:36:24 pm | |||
155.3 USD | -1.10% | 155.2 | -0.06% |
May. 23 | AbbVie Completes Acquisition of Landos Biopharma | MT |
May. 23 | AbbVie Inc. completed the acquisition of Landos Biopharma, Inc. from a group of shareholders. | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With a 2024 P/E ratio at 30.52 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.35% | 277B | C+ | ||
+38.51% | 727B | C+ | ||
+31.97% | 594B | B | ||
-6.23% | 354B | C+ | ||
+18.78% | 328B | B- | ||
+14.75% | 243B | B+ | ||
+7.94% | 205B | B- | ||
-5.69% | 203B | A+ | ||
+6.19% | 164B | C+ | ||
+0.31% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ABBV Stock
- Ratings AbbVie Inc.